---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-009639"
form_type: "8-K"
ticker: "XENE"
cik: "0001582313"
company_name: "Xenon Pharmaceuticals Inc."
filed_at: "2022-03-10T23:59:59+00:00"
generated_at: "2026-06-26T23:58:23.837428+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Xenon: director Hayden not standing for re-election; Pimstone to become Chair; exec comp approved

## Summary
- Michael Hayden will not stand for re-election at June 1, 2022 annual meeting; no disagreement with company.
- Board appointed Dr. Pimstone as Chair of the Board, effective subject to his re-election as director.
- 2022 base salaries: Pimstone $525k, Mortimer $594k, Aulin $425k; retroactive to Jan 1, 2022.
- 2022 performance goals include XEN1101 Phase 3 start and MDD proof-of-concept trial initiation.
- 2021 non-equity incentive payments: Pimstone $450k, Mortimer $400k, Aulin $155k (in USD).

## SEC filing metadata
- accession: 0001564590-22-009639
- form_type: 8-K
- ticker: XENE
- cik: 0001582313
- company_name: Xenon Pharmaceuticals Inc.
- filed_at: 2022-03-10T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582313/000156459022009639/0001564590-22-009639-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582313/000156459022009639/xene-8k_20220309.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-009639
- JSON: https://secwatch.observer/filing/0001564590-22-009639.json
- Plain text: https://secwatch.observer/filing/0001564590-22-009639.txt

## Key facts
- Executive change
  Simon N. Pimstone was appointed as Chair of the Board at Xenon Pharmaceuticals Inc..
  - Action: appointed
  - Role: Chair of the Board
  source text: appointed Dr. Pimstone, current Executive Chair of the Board, as Chair of the Board, effective upon and subject to his re-election as a director at the Annual Meeting.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1582313/000156459022009639/0001564590-22-009639-index.htm
- Executive change
  Michael Hayden departed as Director at Xenon Pharmaceuticals Inc..
  - Action: not stand for re-election
  - Role: Director
  source text: Michael Hayden, notified the Board that he would not stand for re-election as a director of the Board at the Annual Meeting.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1582313/000156459022009639/0001564590-22-009639-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.